- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 16- Exploring the Benefits and Limitations of Available Agents
During this segment, the panelists discuss how new agents have affected the expectations of physicians and patients in terms of overall outcomes. Unfortunately, they conclude that there is some disparity between the expectations and the reality.
Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that our country has not achieved developing a multi-target agent. While certain drugs control certain events, they often lead to other events. Additionally, while treatment with agents such as glucagon-like peptide-1 is presented as a terrific treatment option, there is still a lack in data that demonstrates that it does in fact reduce cardiovascular disease.
Kenneth L. Schaecher, MD, FACP, CPC, agrees with Dr Handelsman but does feel that a benefit of the wide range of available agents has allowed professionals to treat patients with flexibility. Rather than treating a patient off of a specific protocol, this allows patients to be treated with a more personalized therapy concept.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More
